Veriphi is an innovative medical device company that is dedicated to improving patient outcomes by increasing medication accuracy, particularly in intravenous cancer therapy. Our primary objective is to make intravenous drug administration safer and more effective. At the heart of our solution is our flagship product, the Veriphi Flushing Analyser, also known as Ada.

This groundbreaking analyser utilizes lasers to verify the identity and concentration of intravenous drugs, effectively preventing patient harm from medication errors. Initially, our product will be deployed in compounding pharmacies to enhance quality assurance systems. However, we envision a future where our miniaturized analyser can be used at the patient's bedside, whether in a hospital, community setting, or even remote areas.

Globally, the cost associated with medication errors amounts to a staggering $42 billion each year. Our goal is to address this issue by enabling safe and effective administration of oncology drugs to cancer patients, wherever they may be. With the rise of patient-centric models of care, exemplified by the hospital at home approach, Veriphi aims to be at the forefront of this transformative shift.

We have chosen to focus initially on IV oncology treatments due to their high potential for improvement in patient outcomes. Intravenous errors are more likely to cause harm than other drug administration methods, and chemotherapy errors affect a significant percentage of adult and pediatric oncology patients. By targeting this critical area, we can have a meaningful impact on patient safety and well-being.

Veriphi holds a sustainable competitive advantage through our extensive global patent portfolio, which includes eight patents granted in the United States. This first-mover advantage solidifies our position as a leader in the field of medical device innovation. Experience the future of medication accuracy and patient care with Veriphi – revolutionizing intravenous drug administration for safer and more effective treatments